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ABSTRACT 
 
Cell-free DNA has been associated with outcome in several acute conditions including 
two reports concerning the outcomes after cardiac arrest that found association of 
circulating DNA quantities at admission with mortality. The origins of cell-free DNA are 
primarily necrosis and apoptosis, which in cardiac arrest occur during ischemia (“no-
flow” and “low-flow” period), during reperfusion injury and as a consequence of post-
arrest inflammatory response. Respecting the facts that significant cellular damage may 
occur during the post-arrest period, and that that damage might be reduced by mild 
therapeutic hypothermia, we investigated the prognostic value of cell free DNA at ICU 
admission and 24 hours after admission.   
 
A prospective study was conducted in three university associated intensive care units and 
included patients resuscitated from non-traumatic out-of-hospital cardiac arrest. Patient 
data were collected in accordance with the Utstein protocol. Therapeutic hypothermia 
was performed according to ICU policies.  
Blood for cell-free DNA quantification was sampled at admission and at 24±1 hour after 
admission. Outcome measures were hospital morality and cerebral performance 
expressed with CPC scale at discharge.  
 
Inclusion criteria were met in 67 patients; 24-hour mortality was 37.3% and hospital 
mortality 71.6%. The following variables were associated with 24-hour mortality in 
univariate analysis: asystole as the presenting rhythm, “no-flow” time, “low-flow” time 
and cell-free DNA at admission (median 0.081 in survivors vs. 0.160 ng/µl in non-
survivors; P=0.038). Multivariate analysis that included the above variables showed that 
no-flow time and low-flow time were independently associated with 24-hour mortality.  
Hospital mortality was associated with the following factors: “low flow” time, coronary 
intervention, cell-free DNA at ICU admission and at 24 hours after admission (0.042 vs. 
0.188 ng/µl; P=0.048). ROC curve for cell-free DNA 24 h post-admission showed 
sensitivity of 81.0% and specificity of 78.3% for the cut-off value of 0.115 ng/µl.  
Multivariate analysis showed that “low-flow” time and cell-free DNA at 24 hours after 
ICU admission were independently associated with hospital mortality. Cell free DNA 
showed different dynamics in patients who were and who were not treated with mild 
therapeutic hypothermia: it decreased in treated patients and slightly increased in non-
treated patients.  
 
Cell-free DNA quantity at ICU admission and 24 h after admission is associated with 
hospital mortality. Further studies will need to additionally investigate possible practical 
use of this new laboratory marker in patients resuscitated from cardiac arrest. 
INTRODUCTION 
 
Successful resuscitation from cardiac arrest is associated with high morbidity and 
mortality [1]. Some biochemical markers, such as neuron-specific enolase [2] and protein 
S-100B [3], have been associated with outcome after cardiac arrest, but predicting 
outcome in such patients remains an important issue, medical, ethical and economical. 
Over pessimistic predictions may deny active support to patients with a chance for 
recovery and too optimistic predictions could burden the patients and the intensive care 
units with futile intensive care.  
 
Cell-free plasma DNA has been investigated as a diagnostic tool in various conditions 
[4], mainly chronic: autoimmune diseases [5] and cancer [6, 7], but it was also 
investigated and associated with outcome in several acute conditions such as trauma [8], 
stroke [9], myocardial infarction [10], sepsis [11] and acute pancreatitis [12, 13]. 
 
Cell death by apoptosis or necrosis is supposed to be the main source of circulating DNA 
[6, 7, 14], although all the aspects of its origins and clearance are not fully understood. 
Cardiac arrest and post-resuscitation period is associated with cellular necrosis due to 
hypoxia during the no-flow period, but substantial cellular damage also occurs after 
circulation has been restored [1, 15, 16], as a consequence of reperfusion injury and 
inflammatory response. Harmful processes that occur during the post-resuscitation period 
have in the past years been targeted with mild therapeutic hypothermia (MTH) which was 
proven to reduce mortality [17] and was adopted as a recommended treatment in such 
patients [18]. 
 
Two recent papers [19, 20] reported that cell-free DNA, quantified early after 
resuscitation from cardiac arrest, is associated with mortality. In the later paper [19], 
DNA was also quantified 24 hours and 72 hours after arrest, but no significant difference 
associated with hospital mortality was found. Respecting the facts that significant cellular 
damage may occur during the post-arrest period [1], and that that damage might be 
reduced by MTH [18], we investigated the prognostic value of cell free DNA at ICU 
admission and 24 hours after admission.   
 
PATIENTS AND METHODS 
 
This was a prospective study conducted in three intensive care units in hospitals affiliated 
to the University of Zagreb School of Medicine. We included consecutive patients who 
were admitted after a non-traumatic out-of-hospital cardiac arrest and successful 
resuscitation. Inclusion period started on Feb 1st 2010 and ended on Jan 31st 2012. The 
inclusion criteria were: 1) age ≥ 18 years; 2) successful recovery of spontaneous 
circulation within 60 minutes from collapse. The exclusion criteria were: 1) end-stage 
chronic disease or “don-not-resuscitate” order; 2) survival for less than 12 hours after the 
arrest; 3) myocardial infarction (MI), stroke or arrest within 30 days before the index 
event, but not if MI was the admission diagnosis of the index hospitalization 4) failure to 
obtain informed consent from the family. 
 
Patient data were collected in accordance with the Utstein protocol [21]. Cardiac arrest 
was defined as absence of spontaneous respiration and pulse with one of the following 
rhythms: ventricular fibrillation (VF), ventricular tachycardia (VT), pulseless electrical 
activity (PEA) and asystole.  
Therapeutic hypothermia was performed at the discretion of admitting physicians and 
according to ICU policies. If implemented, it was maintained at target core temperature 
33±1 ºC for 24 hours; protocols and methods for cooling and re-warming depended on 
participating ICUs’ policies, but all units used cold saline infusions and external cooling.  
 
Blood samples for cell-free DNA quantification were drawn 1) during the first 30 min 
from ICU admission and 2) at 24±1 hour after admission. Plasma was separated by 
centrifugation immediately after blood draw and stored until analysis at -80 ºC. 
 
Outcome measures were hospital morality and neurological outcome expressed with 
cerebral performance category (CPC) scale [22] at hospital discharge. Six-month 
mortality was also assessed.  
 
Free DNA assay  
DNA was extracted from 100 µl of plasma using DNeasy
®
 Blood and Tissue Kit 
(QIAGEN GmbH, Germany) according to the manufacturer’s protocol. 
Real time PCR was performed using Quantifiler Human DNA Quantification kit 
(Applied Biosystems, USA). A coding region of the human telomerase reverse 
transcriptase gene (hTERT locus located on chromosome 5) was used to quantify total 
DNA. Detailed PCR protocol is described in our previous work [12]. 
Amplification data were collected and analyzed with an ABI Prism 7000 Sequence 
Detection System (SDS) instrument (Applied Biosystems, USA). The cycle threshold 
value (Ct) was measured in all cases. Each sample was analyzed in duplicate, and 
multiple negative reaction blanks were included in every analysis for both sample 
extraction and amplification stages. Calibration curve was analyzed on the same reaction 
plate for each run using quantification standard dilutions [12]. 
 
Statistical analyses 
All analyses were performed using SPSS v17.0 software (SPSS, Chicago, Ill., USA). 
Due to small sample size, continuous data are presented as median with interquartile 
range, discrete variables as absolute and relative frequencies.  
Wilcoxon’s test was used for group comparisons of continuous variables; chi-squared test 
for categorical variables. For correlation analyses, Spearman’s rank correlation was used. 
Multivariate analyses – multiple logistic regression – was performed after univariate 
analyses to investigate which variables were independently associated with an outcome. 
The analyses included variables associated with the dependent variable in univariate 
analysis that did not have significant correlation between them. Statistical significance 
was set at α= 0.05. 
 
The study was approved by ethics committees of the participating hospitals. Patients’ 
next of kin was asked for consent for inclusion in the study; patients who recovered 
consciousness were asked to confirm consent for participation in the study.  
RESULTS  
There were 116 resuscitated patients admitted to participating ICUs during the inclusion 
period. We excluded: 14 terminally ill, 4 with recent MI or stroke, 12 for whom we could 
not get consent and 19 patients who died within 12 hours after arrest.  
The remaining 67 patients had 24-hour mortality, hospital mortality and six-month 
mortality of 37.3%, 71.6% and 72.9% respectively. There were no differences in 
mortalities between the participating centres. The demographic data, comorbidities, arrest 
data, treatment and outcome data are depicted in Table 1.  
 
Univariate analysis showed that the following variables were associated with 24-hour 
mortality: initial rhythm (asystole in 76% survivors, 36% non-survivors; P=0.006), 
defibrillation performed (24% survivors, 52.3% non-survivors; P=0.042), “no-flow” time 
(median 4 min for survivors vs. 5 min for non-survivors; P=0.008), “low-flow” time 
(median 22 min for survivors vs. 31 min for non-survivors; P<0.001) and cell-free DNA 
at ICU admission (median 0.081 ng/µL in survivors vs. 0.160 ng/µL in non-survivors; 
P=0.038).  
Inter-variable analyses showed that initial rhythm was associated with low-flow time and 
with performance of defibrillation; the two variables were thus excluded from the 
multivariate model that showed that no-flow time and initial rhythm were independently 
associated with 24-hour mortality (Table 2).  
 
Hospital mortality was associated with following factors: “low flow” time, coronary 
intervention, cell-free DNA at ICU admission and at 24 hours after admission (Table 1).  
 
Receiver operating characteristic (ROC) curves were constructed to evaluate predictive 
value for hospital mortality (Figure 1). Cell free DNA at 24 hours after admission had 
sensitivity of 81.0% and specificity of 78.3% for the optimal cut-off value of 0.115 
ng/µL; area under ROC curve was 0.762 (95% confidence interval 0.61-0.88). Cell-free 
DNA quantified at admission had the optimal cut-off at 0.092 with sensitivity of 70% and 
specificity of 60.4%; area under ROC curve was 0.636 (95% CI 0.511-0.750).  
 
Multivariate analysis that included variables associated with hospital mortality showed 
that “Low-flow” time and cell-free DNA at 24 hours after ICU admission (dichotomised 
according to the cut-off value of 0.115 ng/µL, optimal from ROC curve) were 
independently associated with hospital mortality (Table 3).  
 
Cell-free DNA at 24 hours was lower in patients who were treated with mild therapeutic 
hypothermia (median 0.038 ng/µL, IQR 0.0173-0.084) compared to patients who were 
not (median 0.172 ng/µL, IQR 0.113-0.423; P=0.048).  
As shown in Figure 2, the quantity of cell-free DNA had a tendency to rise from 
admission (median 0.081 ng/µL, IQR 0.038-0.185) to 24 hours after admission (median 
0.115 ng/µL, IQR 0.048-0.309; P=0.088). In the subgroup of patients who were not 
treated with MTH, the increase in DNA quantity was significant (median 0.086 ng/µL, 
IQR 0.057-0.222 vs. median. 0.167 ng/µL, IQR 0.113-0.423; P=0.034). Patients who 
were treated with MTH had a trend for lower DNA quantities at 24 hours than at 
admission (median 0.038 ng/µL; IQR 0.029-0.143 vs. 0.053 ng/µL, IQR 0.017-0.084; 
P=0.079).  
The difference in DNA quantity from admission to 24 hours after admission was negative 
in patients who were treated with MTH (median -0.041) and positive in patients who 
were not (median 0.87 ng/µL, P=0.039) 
 
Cerebral performance categories had significant positive correlation with plasma cell-free 
DNA quantified 24-hours after admission (r=0.351, P=0.020) and no correlation with 
plasma cell-free DNA quantified at admission (P=0.587).  
 
At six months after the index event, survivors also had significantly lower cell-free DNA 
levels quantified at ICU admission (median 0.302 ng/µL vs. 0.335 ng/µL: P=0.010) and 
at 24 hours after admission (median 0.248 ng/µL vs. 0.368 ng/µL; P=0.048). 
 
DISCUSSION 
The presented study shows that plasma cell-free DNA at ICU admission is associated 
with 24-hour, hospital mortality and six-month mortality. Cell-free DNA quantified at 24 
hours after admission was associated with hospital mortality and CPC score at discharge.  
We also found that treatment with mild therapeutic hypothermia is associated with 
different cell-free DNA temporal pattern i.e. DNA quantities rose in patients who had not 
been treated with MTH.  
 
Only patients with out-of hospital cardiac arrest were included, and a relatively high 
mortality of almost 70% was observed. The reasons for high mortality are speculative. 
Low ratio (only about 20%) of patients with VF as initial rhythm probably is a part of the 
answer since those patients have better prognosis. Relatively long response times by our 
emergency teams could also be in part responsible to high mortality, but also to low ratio 
of VF. Other factors, such as (non-) implementation of MTH also may contribute. 
 
The dynamics of cell-free DNA in plasma after cardiac arrest are not clearly understood. 
Circulating DNA originates from cell necrosis due to hypoxia during the arrest, but also 
from necrosis and apoptosis of cells after the arrest, consequent to complex mechanisms 
that include inflammation, free radical formation, altered calcium homeostasis, 
excitotoxicity, pathological protease cascades and activation of cell death signalling [1].  
 
The anoxic and post-anoxic injuries occur in all organs and cell-free DNA originates 
from all tissues, unlike some other conditions in which circulating DNA was associated 
with outcome, such as stroke [9], myocardial infarction [10] and acute pancreatitis [13].  
In the post-arrest patients, the cerebral and myocardial damage determine the patients’ 
outcome and although circulating DNA originates from all tissues, its quantity is still in 
association with mortality.  
 
Mild therapeutic hypothermia aims to reduce post-arrest damage and consequently 
improve the outcome. Different dynamics of circulating DNA quantities in patients 
treated with MTH should reflect the effects of hypothermia on the detrimental processes 
in the post-arrest period. Although patients treated with MTH had lower cell-free DNA 
levels at 24 hours and MTH was associated with better outcomes (lower mortality of 
treated patients), that difference was not significant, due to low number of patients 
included. 
 
The association of plasma cell-free DNA with the outcome after cardiac arrest has been 
reported in two recent papers. In the first paper by Arnalich and colleagues [20], 
circulating DNA quantity at admission was associated with 24-hour mortality and 
hospital mortality. Huang and colleagues [19] quantified cell-free DNA within 2 hours 
from admission and at 24 hours and 72 hours after admission .They found only admission 
cell-free DNA quantities to be significantly different in 24-hour and hospital survivors 
and non-survivors. Most recently, Arnalich’s group reported that mitochondrial DNA 
quantified within 2 hours after recovery from arrest is better in predicting 3-day survival 
compared to cellular circulating DNA [23].  
 
The major novelty in the present study is superior prognostic value for hospital survival 
of cell-free DNA quantified 24 hours after admission than at admission. Huang’s study 
found differing results, but included fewer patients. Also, the application of MTH is not 
reported in Huang’s study. We found therapeutic hypothermia to be associated with 
dynamics of cell-free DNA quantity and, despite the fact that it showed only trend in 
association with survival, we believe that it is partly responsible for better prognostic 
value of cell free DNA at 24 hours than at admission.  
 
Our study is the first to report correlation between free DNA quantity and cerebral 
performance category score, an outcome measure recommended to be used besides 
survival in evaluating outcomes after cardiac arrest.  
 
The influence of an outcome predictor after resuscitation from cardiac arrest will mostly 
depend on current practice. It has been established that many patients in UK are declared 
“do not attempt resuscitation” and care is withdrawn early in the post-arrest period, when 
proper prognostication is not possible [24, 25]. Positive prognostic signal from a marker 
such as circulating DNA could reduce perception of likely adverse outcome, giving the 
patient a greater chance of recovery. Oppositely, withdrawal of treatment and organ 
donation decisions could be better substantiated with an accurate prognostic marker. 
 
The present study was prospective and multi-centre, conducted according to strict 
procedures and data were collected according to the Utstein protocol. Nonetheless, the 
study has potential weaknesses. The most obvious limitation is the small sample size, 
resulting in model instability in multivariate analyses and relatively weak numbers in 
ROC curve analyses. Larger studies will have to be performed to address these issues.  
Blood sampling and specimen handling is very important factor in ensuring quality 
results [26], since DNA from sample leucocytes can influence the results [27]. We have 
invested additional efforts to ensure optimized sampling and handling in all centres, but 
some differences may still have occurred. The method used for DNA quantification is in 
principle the same as the methods other authors used in clinical research (real time PCR) 
but there are some differences. The gene that is used to quantify DNA is different: most 
authors report using β-globin gene. Also, our method reports DNA quantities in ng/µL, 
instead in genome equivalents as in most studies. Direct comparisons of results are 
therefore not possible, but conversion to genome equivalents can be made (1GE=6.6 pg 
DNA) [28]. 
 
Our results open several new questions that need to be answered in future research. The 
first may be the timing of cell-free DNA quantification. It is well established that harmful 
processes continue for as long as 72 hours after spontaneous circulation has been restored 
after cardiac arrest. Therefore we hypothesised that later quantification of cell-free DNA 
might be more sensitive for outcome, which was correct in our cohort. It is possible that 
dynamics of DNA quantities in serial measurements will be the most sensitive for 
outcome. Future research should include quantification of both cell-free and 
mitochondrial circulating DNA given the recent report [23]. We propose a larger study 
with serial measurements of cellular and mitochondrial DNA, addressing issues of pos-
arrest treatment such as MTH, which could answer some of the remaining issues.  
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FIGURE LEGENDS 
 
Figure 1. Receiver operating characteristic (ROC) curves for prediction of hospital 
mortality using cell-free DNA quantified at ICU admission (dashed line) and 24 
hours after resuscitation from cardiac arrest (full line). Marked are the cut-off values 
with optimal sensitivity-specificity. AUC – area under ROC curve.  
 
Figure 2. Cell free DNA quantities: at admission (white bars) and at 24 hours after 
admission (grey bars) for the whole cohort, patients who were and were not treated 
with mild therapeutic hypothermia. The height of the bar represent median, error 
bars represent first and third quartiles. P values from paired Wilcoxon’s test. 
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Table 1. Description of patients included in the study and association of different 
variables with survival at hospital discharge  
 
  
Full cohort 
(N=69) 
At hospital discharge  
Survivors  
(N=21) 
Non-survivors 
(N=48) 
P 
Age (years)     
Female sex 28 (40.6%) 8 (38.1%) 28 (41.7%) 0.781 
Comorbidities 
- None 
- Hypertension 
- Coronary disease 
- Chronic heart failure  
- COPD 
- Diabetes 
- Obesity 
 
4 (5.8%) 
38 (55.1%) 
20 (29%) 
17 (24.6%) 
18 (26.1%) 
22 (31.9%) 
22 (31.9%) 
 
2 (9.6%) 
11 (52.4%) 
8 (38.1%) 
3 (14.2%) 
5 (23.8%) 
5 (23.8%) 
7 (33.3%) 
 
2 (4.2%) 
27 (56.3%) 
12 (25%) 
14 (29.2%) 
13 (27.1%) 
17 (35.4%) 
15 (31.3%) 
 
0.751 
0.766 
0.270 
0.187 
0.989 
0.502 
0.913 
Type of arrest 
- cardiac in origin 
- respiratory 
- other (i.e. metabolic) 
 
42 (60.9%) 
24 (34.8%) 
3 (4.3%) 
 
15 (71.4%) 
4 (19%) 
2 (9.6%) 
 
27 (56.3%) 
20 (41.6%) 
1 (4.2%) 
 
0.102 
Initial rhythm 
- Ventricular fibrillation 
- Pulseless electrical activity 
- Asystole  
 
13 (18.8%) 
21 (30.4%) 
35 (50.7%) 
 
5 (23.8%) 
8 (38.1%) 
8 (38.1%) 
 
8 (16.7%) 
13 (27.1%) 
27 (56.3%) 
 
0.382 
Resuscitation 
- Time to resuscitation (“no-flow”, min) 
- Resuscitation time (“low-flow”, min) 
- Witnessed arrest 
- Bystander CPR 
- CPR at admission to ED 
- Defibrillation 
 
4 (2-6) 
26 (20-37) 
42 (60.9%) 
17 (24.6%) 
39 (56.5%) 
29 (42%) 
 
4 (1.75-5.25) 
20 (13.75-23-25) 
14 (29.2%) 
7 (33.3%) 
7 (33.3%) 
10 (47.6%) 
 
4 (3-6) 
30 (23.5-39) 
28 (58.3%) 
10 (20.8%) 
32 (68.8%) 
19 (39.6%) 
 
0.209 
<0.001 
0.514 
0.268 
0.021 
0.534 
Treatment 
- comatose at ICU admission 
- Mild therapeutic hypothermia 
- Acute myocardial infarction 
- Coronary angiography  
- Coronary intervention 
- Cardiogenic shock  
- Intra-aortic balloon pump 
 
63 (91.3%) 
32 (46.4%) 
33 (47.8%) 
27 (39.1%) 
17 (24.6%) 
13 (18.8%) 
2 (2.9%) 
 
18 (85.7%) 
12 (57.1%) 
13 (59.1%) 
11 (52.4%) 
8 (38.1%) 
3 (14.2%) 
- 
 
45 (93.8%) 
20 (41.7%) 
20 (41.7%) 
16 (33.3%) 
7 (14.6%) 
10 (20.8%) 
2 (4.2%) 
 
0.276 
0.236 
0.121 
0.136 
0.029 
0.522 
0.865 
Cell free DNA (ng/µL) 
- admission to ICU 
 
- 24 hours after admission 
 
0.093  
(0.038-0.185) 
0.117 
(0.037-0.309) 
 
0.057 
(0.023-0.145) 
0.042 
(0.021-0.102) 
 
0.108 
(0.048-0.210) 
0.188 
(0.121-0.388) 
 
0.048 
 
0.003 
Values are medians with inter-quartile ranges or absolute and relative frequencies. 
COPD – Chronic obstructive pulmonary disease; CPR – cardiopulmonary resuscitation: ED – emergency 
department; ICU – intensive care unit 
 
 
 
 
Table 2. Multivariate analysis of factors associated with 24-hour survival.  
Included are variables that were associated with 24-hour mortality in univariate analyses 
and showed no inter-variable correlation.  
 
Variable O.R. (95% CI) P 
“No-flow” time (for each additional minute) 0.69 (0.54 – 0.89) 0.004 
Initial rhythm  0.29 (0.12 – 0.74) 0.009 
Cell free DNA at ICU admission (ng/µL) 1.52 (0.02 – 108.05) 0.826 
 
 
Table 3. Multivariate analysis of factors associated with hospital survival 
 
Variable O.R. (95% CI) P 
Cell free DNA at ICU admission <0.092 ng/µL 6.21 (0.59 – 65.24) 0.128 
Cell free DNA 24h after admission <0.115 ng/µL 72.81 (3.76 – 1411.86) 0.0046 
Coronary intervention 4.58 (0.25 – 81-46) 0.300 
“Low-flow” time (for each additional minute) 0.80 (0.67 – 0.96) 0.019 
 
 
